Immune cell therapy shows promise for tough autoimmune conditions

NCT ID NCT06614270

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Nov 24, 2025 · Last updated May 22, 2026 · Updated 22 times

Summary

This study tests a new treatment using specially engineered immune cells (CAR-NK) from cord blood for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't improved with standard treatments. The goal is to see if a single infusion can safely control the disease by targeting and calming overactive immune cells. The trial involves 15 participants and will closely monitor side effects and disease activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

the second affiliated hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310005, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ANCA-ASSOCIATED VASCULITIS (AAV) ANTIPHOSPHOLIPID SYNDROME IDIOPATHIC INFLAMMATORY MYOPATHY (IIM) SJOGREN'S SYNDROME SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC SCLEROSIS (SSC) SYSTEMIC SCLEROSIS (SSC)